Financial Performance - Operating income for the reporting period increased by 14.07% to ¥121,692,172.68, while year-to-date revenue rose by 14.17% to ¥335,019,179.49[8] - Net profit attributable to shareholders increased by 46.29% to ¥5,625,786.33 for the reporting period, and year-to-date net profit rose by 23.87% to ¥17,025,565.11[8] - The weighted average return on net assets increased to 0.74%, up from 0.35% in the previous year[8] - Investment income increased by 96.97% to ¥446,600, driven by profit growth from the associated enterprise Huqingyuan[17] - Sales revenue for the first three quarters of 2018 increased by 14.17% compared to the same period last year, indicating improved market performance[33] - The performance recovery is attributed to improved sales conditions at its subsidiary, Jinsan Pharmaceutical, which may not require goodwill impairment provisions in 2018[33] Cash Flow - The net cash flow from operating activities surged by 285.50% to ¥15,286,065.23 during the reporting period[8] - Cash received from operating activities increased by CNY 10.3013 million, a growth of 574.40% year-on-year, mainly due to tax payments and repayments from subsidiaries[18] - Net cash flow from operating activities increased by CNY 24.418 million, a growth of 267.39% year-on-year, primarily driven by increased cash received from sales[18] - Cash received from the disposal of fixed, intangible, and other long-term assets decreased by CNY 1.8925 million, a decline of 46.56% year-on-year, due to reduced cash from asset disposals[18] - Cash paid for the acquisition of fixed, intangible, and other long-term assets decreased by CNY 10.217 million, a decline of 62.79% year-on-year, attributed to reduced investment compared to the previous year[18] - Net cash flow from investing activities increased by CNY 12.5745 million, a growth of 76.41% year-on-year, mainly due to decreased cash payments for fixed asset construction[18] - Cash received from borrowings decreased by CNY 12 million, a decline of 40.00% year-on-year, primarily due to reduced bank borrowings[19] - Cash paid for debt repayment increased by CNY 18.10 million, a growth of 90.95% year-on-year, mainly due to increased loan repayments by subsidiaries[19] - Net cash flow from financing activities decreased by CNY 15.9354 million, a decline of 309.25% year-on-year, due to reduced borrowings and increased repayments[19] Assets and Liabilities - Total assets at the end of the reporting period decreased by 2.23% to ¥857,048,415.73 compared to the end of the previous year[8] - Accounts receivable decreased by 30.29% to ¥44,941,000 due to enhanced collection efforts[16] - Short-term borrowings decreased by 50% to ¥20,000,000 as the company repaid ¥38,000,000 in bank loans[16] - Prepayments increased by 118.03% to ¥2,821,000, primarily due to higher advance payments for raw materials and equipment[16] Profit Distribution - The company plans to distribute profits in cash, with a minimum of 10% of the annual distributable profit allocated each year for the next three years[30] - Cumulative cash distributions over the three years should not be less than 30% of the average annual distributable profit achieved during that period[30] - The company plans to distribute cash dividends, with a minimum of 80% of profits allocated for mature stages of development[32] - The company has committed to conducting cash dividends annually for the next three years, subject to meeting distribution conditions[32] - The company is in a growth phase and considers stock dividends as a potential method for profit distribution[32] Corporate Governance - The company will avoid transactions with related parties to ensure fairness and compliance with legal regulations[26] - The management team will not participate in any operational or management activities of the company for three years following the issuance[28] - The company commits to maintaining a fair pricing mechanism for transactions with independent third parties[27] - The company emphasizes the importance of maintaining the legal rights and interests of its shareholders during transactions[26] - The company has committed to ensuring that transactions do not harm the interests of non-related shareholders[27] - The company will adhere to the principles of equality, voluntariness, and compensation in its transactions[26] - The company has no reported non-operating fund occupation by controlling shareholders or related parties during the reporting period[36] - There were no instances of entrusted financial management during the reporting period[37] - The company has no violations regarding external guarantees during the reporting period[35] Future Outlook - The company expects a net profit for 2018 to be between 20 million and 45 million CNY, compared to a net loss of 214.76 million CNY in 2017[33] - The company aims to enhance market share through increased marketing investment and sales channel integration[33] - The company will actively consider industry characteristics and development stages when proposing differentiated cash dividend policies[30]

广东嘉应制药股份有限公司 2018 年半年度报告全文 广东嘉应制药股份有限公司 2018 年半年度报告 2018-071 2018 年 08 月 1 广东嘉应制药股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人陈建宁、主管会计工作负责人宋稚牛及会计机构负责人(会计主 管人员)陈晓燕声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 报告期内可能存在行业政策变化、主导产品较为集中、市场竞争加剧、新 药开发等风险，详见本报告第四节"经营情况讨论与分析" 的"十、公司未来发 展的展望" 中对公司可能面临风险的相关描述，敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 2018 | 年半年度报告 2 | | --- | --- | | 第一节 | 重要提示、释义 2 | | 第二节 | 公司简介和主要财务指标 5 ...

广东嘉应制药股份有限公司 2018 年第一季度报告正文 证券代码：002198 证券简称：嘉应制药 公告编号：031 广东嘉应制药股份有限公司 2018 年第一季度报告正文 1 广东嘉应制药股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 93,430,702.81 | 78,461,064.68 | 19.08% | | 归属于上市公司股东的净利润（元） | 8,456,582.31 | 7,835,931.73 | 7.92% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 8,317,203.89 | 7,837,030.76 | 6.13% | | 经营活动产生的现金流量净额（元） | -6,698,245.46 | -15,249,516.29 | -56.08% ...

Financial Performance - The company's operating revenue for 2017 was CNY 468,080,735.66, representing a 4.03% increase compared to CNY 449,950,868.63 in 2016[17]. - The net profit attributable to shareholders of the listed company was CNY -214,761,693.31, a decrease of 489.26% from CNY 55,172,042.10 in the previous year[17]. - The net cash flow from operating activities was CNY 30,631,917.68, down 42.34% from CNY 53,126,869.00 in 2016[17]. - The total assets at the end of 2017 were CNY 876,610,240.21, a decrease of 20.25% from CNY 1,099,254,401.78 at the end of 2016[18]. - The net assets attributable to shareholders of the listed company were CNY 749,810,780.63, down 23.87% from CNY 984,872,497.95 in 2016[18]. - The basic earnings per share for 2017 were CNY -0.4232, a decline of 489.33% from CNY 0.1087 in 2016[17]. - The weighted average return on net assets was -24.62% in 2017, down from 5.76% in 2016[18]. - The company reported a significant loss in the fourth quarter, with a net profit of CNY -228,506,632.31[21]. - The company reported a government subsidy of 1,169,458.33 in 2017, a significant increase from 38,404.50 in 2016[24]. - Non-operating income and expenses amounted to -90,142.19 in 2017, compared to -71,419.84 in 2016[24]. - The company’s non-current asset impairment loss was -208,136.28 in 2017, an increase from -27,314.33 in 2016[23]. - The company’s total non-recurring gains and losses for the reporting period were 621,445.51, a recovery from -41,965.53 in 2016[24]. Market and Industry Context - The pharmaceutical industry in China saw a 12.1% increase in value-added output in 2017, indicating a recovery in growth rates[29]. - The implementation of the "two-invoice system" in drug procurement is expected to reduce drug prices and increase industry concentration[30]. - The company faces intensified market competition with over 1,000 traditional Chinese medicine manufacturers in China, prompting strategies for mergers and acquisitions to strengthen market position[74]. Product and R&D Development - The company has a total of 65 drug varieties across 5 dosage forms, focusing on traditional Chinese medicine[27]. - The company continued to invest in research and development, collaborating with South China University of Technology on key technology for the extraction of essential oils from plum trees[39]. - New drug development projects include the anti-diabetic drug Sangpizhen capsules and a collaborative project with Jinan University on anti-tumor nano-drugs, although these projects carry inherent risks due to lengthy development cycles[75]. - The company plans to launch three new products in the next quarter, which are anticipated to contribute an additional 200 million RMB in revenue[93]. Financial Management and Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has established mechanisms to ensure the protection of minority shareholders' rights and interests[82]. - The cash dividend policy is compliant with the company's articles of association and shareholder resolutions[82]. - The company has fulfilled its commitments regarding avoiding competition and related transactions as of the reporting date[87][88]. - The company has a robust internal audit department directly accountable to the audit committee, ensuring effective oversight of financial practices[185]. - The audit committee held 4 meetings in 2017 to review the audit department's work plans and financial reports, ensuring the independence of the audit process[195]. Employee and Management Structure - The company employed a total of 1,122 staff, with 405 in production, 460 in sales, and 133 in technical roles[164]. - The total remuneration for directors, supervisors, and senior management in 2017 amounted to CNY 1.9395 million[161]. - The employee compensation policy is based on a tiered salary system, linking salary levels to company performance and individual contributions[166]. - The training program focuses on enhancing overall employee capabilities, with specific emphasis on middle and senior management skills[167]. Future Outlook and Strategic Plans - The company provided a future outlook projecting a revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion[94]. - The company plans to reform marketing strategies to enhance brand recognition and market competitiveness, focusing on terminal market development in Guangdong[69]. - A strategic acquisition of a local pharmaceutical company is in progress, expected to enhance the product portfolio and distribution channels[92]. - The company aims to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next three years[96].

Financial Performance - Operating revenue for the reporting period was ¥106,681,384.91, down 1.75% year-on-year, while revenue for the year-to-date reached ¥293,433,938.96, an increase of 6.82%[8] - Net profit attributable to shareholders for the reporting period was ¥3,845,652.81, a decline of 14.06%, with year-to-date net profit at ¥13,744,939.00, down 32.68%[8] - Basic earnings per share for the reporting period were ¥0.0076, down 13.64%, with diluted earnings per share also at ¥0.0076[8] - The weighted average return on net assets was 0.39%, a decrease of 0.08% compared to the previous year[8] - The net profit attributable to shareholders for 2017 is expected to decline by 31.12% to 38.37%, with an estimated range of 34 million to 38 million CNY[26] - The net profit for 2016 was 55.172 million CNY, indicating a significant decrease in profitability for 2017[26] - The decline in net profit is attributed to increased employee wages, rising raw material costs, and higher sales expenses due to market expansion efforts[26] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥8,240,452.47, a significant decrease of 214.74% compared to the same period last year[8] - Cash flow from operating activities decreased by 11,017,000 yuan, a decline of 584.47%, primarily due to reduced receivables and increased payments to employees[18] - Cash flow from financing activities decreased by 7,535,500 yuan, a decline of 316.27%, mainly due to increased repayment of bank loans and cash dividends paid[20] - Cash and cash equivalents decreased by ¥30,741,700, a drop of 41.92%, primarily due to repayment of bank loans and cash dividends paid[15] - Inventory increased by ¥20,496,200, an increase of 42.55%, attributed to expanded production and increased raw material purchases[15] - Cash received from the disposal of fixed assets increased by 4,048,000 yuan, an increase of 24,831.45%, due to increased cash from the disposal of properties and vehicles[19] - Cash paid for the acquisition of fixed assets increased by 11,245,000 yuan, an increase of 223.73%, mainly due to increased investment in the construction of the company gate[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,477, with the top ten shareholders holding a combined 56.66% of shares[11] - The company plans to distribute at least 10% of the distributable profit in cash annually over the next three years, with a cumulative distribution of no less than 30% of the average annual distributable profit[25] - Cash dividends are expected to account for at least 80% of profit distribution when the company is in a mature stage without major capital expenditures[25] Commitments and Compliance - The company reported a commitment to avoid any business activities that may compete with its subsidiaries, ensuring no direct or indirect involvement in competing businesses[22] - The commitment includes a promise to maintain fair and equitable transactions with its subsidiaries, adhering to legal and regulatory requirements[23] - The company guarantees to compensate for any economic losses caused to its subsidiaries due to violations of the commitments made[22] - The commitment to avoid conflicts of interest is legally binding and effective from the date of signing[22] - The company emphasizes the importance of fair pricing in transactions with independent third parties to ensure price fairness[23] - The company has not engaged in any related party transactions that could harm the interests of its subsidiaries or non-related shareholders[22] - The company will ensure that no illegal transfer of funds or profits occurs between itself and its subsidiaries[22] - There are no existing agreements or arrangements for concerted actions with other parties involved in the current issuance, ensuring independence in operations[23] - The company will not participate in the management or nomination of directors and senior management of its subsidiaries for three years following the completion of the issuance[23] Other Financial Metrics - Long-term deferred expenses decreased by 375,300 yuan, a decline of 45.41%, mainly due to the amortization of public transportation fees and waste treatment costs[16] - Deferred income tax assets increased by 3,600,400 yuan, an increase of 42.72%, primarily due to the decline in net profit of subsidiary Jiaying Pharmaceutical during the reporting period[16] - Short-term borrowings increased by 10,100,000 yuan, an increase of 50.75%, mainly due to the increase in bank loans during the reporting period[16] - Employee compensation payable decreased by 4,242,900 yuan, a decline of 45.91%, mainly due to the payment of the 2016 year-end bonus during the reporting period[16] - Other non-current assets decreased by 5,055,600 yuan, a decline of 100.00%, primarily due to the reduction in prepaid equipment and project payments[16] Investor Relations - The company is actively engaging with investors, as evidenced by an on-site investigation conducted on June 22, 2017[29] - The company is focused on maintaining a balance between capital expansion and performance growth while ensuring adequate cash dividend distribution[25] - There are no reported violations regarding external guarantees during the reporting period[27] - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[28]

2017-031 2017 年 08 月 1 广东嘉应制药股份有限公司 2017 年半年度报告全文 广东嘉应制药股份有限公司 2017 年半年度报告全文 第一节 重要提示、目录和释义 广东嘉应制药股份有限公司 2017 年半年度报告 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人陈泳洪、主管会计工作负责人黄利兵及会计机构负责人(会计主 管人员)陈晓燕声明：保证本半年度报告中财务报告的真实、准确、完整。 广东嘉应制药股份有限公司 2017 年半年度报告全文 释义 | 释义项 | 指 | 释义内容 | | --- | --- | --- | | 公司、本公司、嘉应制药 | 指 | 广东嘉应制药股份有限公司 | | 嘉应医药 | 指 | 广东嘉应医药有限公司 | | 湖南金沙、金沙药业 | 指 | 湖南金沙药业有限责任公司 | | 华清园、华清园生物 | 指 | 广东华清园生物科技有限公司 | | 中国证监会 | 指 | 中国证券监督管理委员会 | | 广东证监局 | 指 | 中国证券监督管理委员会 ...

Financial Performance - The company's operating revenue for 2016 was ¥449,950,868.63, a decrease of 5.43% compared to ¥475,805,044.29 in 2015[17] - The net profit attributable to shareholders for 2016 was ¥55,172,042.10, down 16.85% from ¥66,354,921.06 in 2015[17] - Basic earnings per share for 2016 were ¥0.1087, a decline of 16.83% from ¥0.1307 in 2015[17] - The weighted average return on equity decreased to 5.76% in 2016 from 7.40% in 2015, a drop of 1.64%[17] - The company reported a quarterly revenue of ¥175,253,191.08 in Q4 2016, with a net profit of ¥34,754,844.94 attributable to shareholders[21] - The company reported a net profit of CNY 55.172 million in 2016, with a cash dividend payout ratio of 0.00%[89] - The company cited macroeconomic slowdown, intensified market competition, and rising costs as factors leading to a year-on-year decline in net profit for 2016[89] Cash Flow and Investments - The net cash flow from operating activities increased by 25.56% to ¥53,126,869.00 in 2016, compared to ¥42,312,921.81 in 2015[17] - Total cash inflow from operating activities decreased by 9.94% to CNY 469,674,626.90 from CNY 521,511,683.81 in 2015[58] - Cash outflow from operating activities decreased by 13.07% to CNY 416,547,757.90 from CNY 479,198,762.00 in 2015[58] - Investment cash inflow significantly dropped by 99.56% to CNY 76,834.95 from CNY 17,342,296.49 in 2015, primarily due to the recovery of financial products in the previous year[59] - The net cash flow from investment activities was CNY -14,404,025.81, an improvement of 37.59% compared to CNY -23,078,365.20 in 2015[59] - Cash inflow from financing activities decreased by 56.34% to CNY 19,900,000 from CNY 45,577,655.87 in 2015, mainly due to a reduction in bank loans[59] Assets and Liabilities - Total assets at the end of 2016 were ¥1,099,254,401.78, reflecting a 4.89% increase from ¥1,047,997,444.15 at the end of 2015[17] - The net assets attributable to shareholders increased by 5.93% to ¥984,872,497.95 at the end of 2016, compared to ¥929,700,455.85 at the end of 2015[17] - As of the end of 2016, cash and cash equivalents increased to CNY 73,334,124.78, representing 6.67% of total assets, up from 4.41% in 2015[64] - The company's fixed assets decreased to CNY 257,669,405.70, representing 23.44% of total assets, down from 26.25% in 2015[64] - The company's total assets included CNY 152,903,709.02 in accounts receivable, which accounted for 13.91% of total assets, an increase from 13.53% in 2015[64] Market and Industry Trends - The pharmaceutical industry in China saw a 10.6% year-on-year increase in the added value of the pharmaceutical industry in 2016, indicating a recovery trend[28] - The demand for pharmaceuticals is expected to grow due to increasing income levels and an aging population in China[28] - The South China region experienced a significant revenue decline of 45.34%, with total sales of CNY 55.47 million, while the East China region saw an increase of 82.07% to CNY 158.27 million[47] Research and Development - The company has completed key research projects related to natural camphor and is in the acceptance phase for several innovative development projects[39] - The company has initiated a collaboration with Jinan University on an anti-tumor nano-drug project, which is currently in the preclinical research stage[40] - Research and development expenses amounted to CNY 11.20 million, representing 2.49% of total revenue, a slight decrease from 2.57% in the previous year[57] - The company reported a total of 94 R&D personnel, an increase of 3.30% from the previous year, indicating a focus on innovation and product development[57] Governance and Compliance - The company has established a comprehensive governance framework, ensuring clear responsibilities and checks among the shareholders, board of directors, and management[162] - The company has maintained a consistent governance structure with independent directors contributing to oversight and strategic decisions[147] - The company adheres to strict information disclosure practices, ensuring timely and accurate communication with investors[173] - The company has established a dedicated internal audit department to ensure compliance and effective oversight of financial activities[175] Shareholder Relations and Dividends - The company plans to retain profits for operational needs, market expansion, and new product development, rather than distributing dividends[89] - The board of directors proposed not to distribute profits or increase capital stock in light of the company's current financial situation and growth stage[90] - The company commits to distributing cash dividends of no less than 10% of the distributable profits each year for the next three years, with a cumulative distribution of at least 30% of the average annual distributable profits over the same period[96] Risks and Challenges - The company faces risks related to industry policy changes, product concentration, intensified market competition, and new drug development[4] - The company is exploring external growth opportunities through acquisitions and partnerships to enhance its market competitiveness and profitability[78] - The company anticipates sufficient operating cash flow to meet its production needs but will seek additional financing for expansion and asset acquisition[80]

广东嘉应制药股份有限公司 2017 年第一季度报告正文 1 广东嘉应制药股份有限公司 2017 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 广东嘉应制药股份有限公司 2017 年第一季度报告正文 证券代码：002198 证券简称：嘉应制药 公告编号：2017-023 公司负责人陈泳洪、主管会计工作负责人黄利兵及会计机构负责人(会计主 管人员)陈晓燕声明：保证季度报告中财务报表的真实、准确、完整。 2 广东嘉应制药股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 78,461,064.68 | 73,401,318.83 | 6.89% | | 归属于上市 ...

广东嘉应制药股份有限公司 2016 年年度报告全文 广东嘉应制药股份有限公司 2016 年年度报告 2017-010 2017 年 04 月 1 广东嘉应制药股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人陈泳洪、主管会计工作负责人黄利兵及会计机构负责人(会计主 管人员)钟苑苑声明：保证年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议 | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | | 黄雅敏 | 董事 | 个人原因 | | | 李祥厚 | 董事 | 个人原因 | | 本报告中如有涉及未来发展陈述，属于计划性事项，均不构成公司对投资 者的实质承诺，敬请广大投资者注意投资风险。 报告期内可能存在行业政策变化、主导产品较为集中、市场竞争加剧、新 药开发等风险，详见本报告第四节"经营情况讨 ...

广东嘉应制药股份有限公司 2016 年第三季度报告正文 证券代码：002198 证券简称：嘉应制药 公告编号：2016-025 广东嘉应制药股份有限公司 2016 年第三季度报告正文 1 广东嘉应制药股份有限公司 2016 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈泳洪、主管会计工作负责人黄利兵及会计机构负责人(会计主 管人员)钟苑苑声明：保证季度报告中财务报表的真实、准确、完整。 2 广东嘉应制药股份有限公司 2016 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,055,935,473.41 | | 1,047,997,44 ...